SiteOne Therapeutics, a clinical-stage biopharmaceutical company, has received a grant of up to USD 15 million from the National Institute on Drug Abuse (NIDA). This brings the total funds raised by the company to USD 34.2 million. 

The grant was awarded to SiteOne Therapeutics for the development of its drug candidate, STC-004, an investigational non-opioid treatment for acute and chronic pain conditions. The grant will be released in phases based on specific milestones to be completed within a two-year period. After the successful completion of these milestones, further funding will be provided for an additional three years. 

Montana-based SiteOne Therapeutics is a biopharmaceutical company synthesizing small molecule inhibitors to treat hypersensitivity disorders such as chronic pain, itch, and cough. The company’s candidates target voltage-gated sodium ion channels, including NaV1.7 and NaV1.8, with the company synthesizing candidates without the addiction and side effects of opioids. The company is also advancing additional candidates that will be used in the treatment of additional hypersensitivity disorders such as chronic cough and chronic ocular surface pain.